The Patient-Centered Outcomes Research Institute (PCORI) has approved funding awards totaling more than $156 million for new patient-centered comparative clinical effectiveness research (CER), as well ...

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...

Chronic diarrhea can be a frustrating and exhausting condition. It’s more than just an inconvenience—it can seriously affect ...

A new study from The Hospital for Sick Children (SickKids) and Institut Curie reveals how stem cells sense and respond to their environment, with implications for inflammatory bowel disease and ...

Factors portending the greatest risk for cardiovascular death in control patients were inflammation (baseline plasma high-sensitivity C-reactive protein ≥2 mg/L; p=0.003) and ischemic HFrEF etiology ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...

A new study from The Hospital for Sick Children (SickKids) and Institut Curie reveals how stem cells sense and respond to ...

The chronic condition can cause abdominal pain, diarrhea, bloody stools and fatigue. New research suggests it affects more ...

Cases of inflammatory bowel disease (IBD) are rising at an alarming rate among young Americans, a new study reveals.

A study reveals a sharp rise in inflammatory bowel disease (IBD) among American youth, with over 100,000 under 20 affected.